Clinical Trials
7 trialsNCT04704661 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03330847 2026-03-10
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
Phase 2 Active not recruiting
NCT04090567 2026-03-05
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05582538 2025-08-24
ATRiBRAVE
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Recruiting
NCT03740893 2025-08-11
PHOENIX
Institute of Cancer Research, United Kingdom
Phase 2 Recruiting
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown